ASX:OCCOrthocell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orthocell Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.38 +0.02 (+5.48 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.37Now: A$0.39▼A$0.3950-Day RangeA$0.39MA: A$0.39▼A$0.3952-Week RangeA$0.18Now: A$0.39▼A$0.68Volume669,530 shsAverage VolumeN/AMarket Capitalization$71.11 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Orthocell. Previous Next 1.6 Community Rank Outperform VotesOrthocell has received 6 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrthocell has received 13 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrthocell has received 68.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Orthocell and other stocks. Vote “Outperform” if you believe OCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrthocell does not currently pay a dividend.Dividend GrowthOrthocell does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orthocell insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Orthocell is -8.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orthocell is -8.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrthocell has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.32 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:OCC Previous Symbol CUSIPN/A CIKN/A Webwww.orthocell.com.au Phone61 8 9360 2888Debt Debt-to-Equity RatioN/A Current Ratio13.63 Quick Ratio13.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$806,877.00 Price / Sales88.13 Cash FlowA$0.11 per share Price / Cash Flow3.41 Book ValueA$0.13 per share Price / Book2.94Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares184,699,008Market Cap$71.11 million Next Earnings DateN/A OptionableNot Optionable Receive OCC News and Ratings via Email Sign-up to receive the latest news and ratings for OCC and its competitors with MarketBeat's FREE daily newsletter. Orthocell (ASX:OCC) Frequently Asked Questions How has Orthocell's stock been impacted by COVID-19 (Coronavirus)? Orthocell's stock was trading at A$0.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OCC stock has increased by 18.5% and is now trading at A$0.39. View which stocks have been most impacted by Coronavirus. Has Orthocell been receiving favorable news coverage? Media coverage about OCC stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Orthocell earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Orthocell. Who are some of Orthocell's key competitors? Some companies that are related to Orthocell include IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR), OncoCyte (OCX), Theratechnologies (TH), Exicure (XCUR), Novacyt (NCYT), Tiziana Life Sciences (TILS), IMV (IMV), Rafael (RFL) and Pfenex (PFNX). View all competitors. What other stocks do shareholders of Orthocell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), VIRALYTICS Ltd/S (VRACY) and GP Strategies (GPX). Who are Orthocell's key executives? Orthocell's management team includes the following people: Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 49)Mr. Paul Anderson, CEO, MD & Exec. Director (Age 53)Ms. Nicole Telford, Chief Financial OfficerProf. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory BoardMonique Cannon, Regulatory Affairs & Compliance Mang. What is Orthocell's stock symbol? Orthocell trades on the ASX under the ticker symbol "OCC." What is Orthocell's stock price today? One share of OCC stock can currently be purchased for approximately A$0.39. How big of a company is Orthocell? Orthocell has a market capitalization of $71.11 million and generates $806,877.00 in revenue each year. What is Orthocell's official website? The official website for Orthocell is www.orthocell.com.au. How can I contact Orthocell? The company can be reached via phone at 61 8 9360 2888. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
